CaMKII as a therapeutic target in catecholaminergic polymorphic ventricular tachycardia type 1

Back

EHRA Premium Access

CaMKII as a therapeutic target in catecholaminergic polymorphic ventricular tachycardia type 1

Session: Oral abstract session - WGCCE

Topic: Arrhythmias

Speaker: Mr M. Sadredini (Oslo, NO)

Event: EHRA 2021

Congress Presentation

Add to my library

About the speaker

Mr Mani Sadredini

University of Oslo, Oslo (Norway)

1 presentation

0 follower

8 more presentations in this session

Desmosomal vulnerability renders left atria more susceptible to detrimental effects of androgenic anabolic steroids

Speaker: Ms L. Sommerfeld (Hamburg, DE)

The SCN5A point mutation M1875T, associated with familial atrial fibrillation, causes a gain-of-function effect of the cardiac Nav1.5 channel in atrial cardiomyocytes

Speaker: Doctor M. O'Reilly (Amsterdam, NL)

OPN5 a new optogenetic receptor to study Gq signalling in the heart with light

Speaker: Mr A. Wagdi Mohamed (Goettingen, DE)

Clinical, genetic and functional analysis of R562S-Kv7.1 mutation associated with long QT syndrome type 1

Speaker: Doctor O. Svecova (Brno, CZ)

When multiple caveolins make the difference: Cav1 partly compensates Cav3 alterations and rescues ion channels expression.

Speaker: Doctor P. Benzoni (Milan, IT)

Access the full session

Oral abstract session - WGCCE

Speakers: Mr M. Sadredini, Ms L. Sommerfeld, Doctor M. O'Reilly, Mr A. Wagdi Mohamed, Doctor O. Svecova...

Access

About the event

EHRA 2021

23 April - 25 April 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources